Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability.

Purpose Pulmonary arterial hypertension (PAH) is a severe and progressive disease. The prostacyclin analogue iloprost is effective against PAH, but requires six to nine inhalations per day. The feasibility of liposomes to provide a sustained release formulation to reduce inhalation frequency is evaluated from a technological point of view.